PSA

Established

PSA is a widely used prostate cancer marker, but its screening role remains a genuinely preference-sensitive decision.

Also known as KLK3 prostate-specific antigen

In plain language

PSA is a prostate protein used to detect and monitor prostate cancer, but whether to get screened for it is a personal decision that should involve weighing real risks of over-treatment, not an automatic yes for every man.

Biomarker & context

KLK3 encodes prostate-specific antigen (PSA), a protein produced by prostate tissue; elevated blood levels are used to help detect and monitor prostate cancer, though PSA is produced by both benign and malignant prostate tissue.

What it indicates

PSA is established as a diagnostic and monitoring test, but its use as a population screening tool remains genuinely contested due to overdetection and overtreatment of clinically indolent, slow-growing prostate cancer.

Diagnosis & clinical testing

USPSTF recommends shared decision-making for men aged 55-69, and recommends against routine screening in men 70 and older, while men at higher risk (Black men, family history) may reasonably start discussing screening earlier, around age 40-45.

Guiding treatment

The harms of PSA screening are substantial enough that guidelines treat it as a preference-sensitive decision: overdetection and overtreatment of indolent cancer causes real complications (incontinence, erectile dysfunction) from treating disease that may never have caused harm, so a purely factual, non-directive discussion is recommended over automatic testing.

Clinical significance

Guidelines emphasize shared decision-making given real overdetection/overtreatment risks, rather than routine screening for all.

References

USPSTF. Prostate Cancer Screening Recommendation.
droracle.ai. (2025). Current guidelines for PSA screening for prostate cancer.